Personalized medicine in action: Invention of crizotinib (PF-02341066)

被引：0
|
作者：
Cui, J. Jean [1 ]
机构：
[1] Pfizer Inc, Oncol Med Chem, San Diego, CA 92130 USA
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2012年 / 244卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
3-MEDI
引用
收藏
页数：1
相关论文
共 48 条
  • [1] Effect on retinal function as a mechanism for vision disorders with crizotinib (PF-02341066)
    Matsumoto, Diane
    Liu, Chang-Ning
    Somps, Chris
    Wilner, Keith
    Skillings, Jamey
    Burns-Naas, Leigh Ann
    [J]. CANCER RESEARCH, 2011, 71
  • [2] Fit-for-Purpose Development of the Enabling Route to Crizotinib (PF-02341066)
    de Koning, Pieter D.
    McAndrew, Douglas
    Moore, Robert
    Moses, Ian B.
    Boyles, David C.
    Kissick, Kyle
    Stanchina, Corey L.
    Cuthbertson, Timothy
    Kamatani, Asayuki
    Rahman, Leera
    Rodriguez, Rick
    Urbina, Armando
    Sandoval, Alison
    Rose, Peter R.
    [J]. ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2011, 15 (05) : 1018 - 1026
  • [3] Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) in Gastric Cancer Positive for MET Amplification
    Okamoto, Wataru
    Okamoto, Isamu
    Arao, Tokuzo
    Kuwata, Kiyoko
    Hatashita, Erina
    Yamaguchi, Haruka
    Sakai, Kazuko
    Yanagihara, Kazuyoshi
    Nishio, Kazuto
    Nakagawa, Kazuhiko
    [J]. MOLECULAR CANCER THERAPEUTICS, 2012, 11 (07) : 1557 - 1564
  • [4] ANTITUMOR ACTION OF THE MET TYROSINE KINASE INHIBITOR CRIZOTINIB (PF-02341066) IN GASTRIC CANCER POSITIVE FOR MET AMPLIFICATION
    Okamoto, W.
    Okamoto, I.
    Arao, T.
    Nishina, S. -i.
    Ueda, S.
    Kawakami, H.
    Yanagihara, K.
    Kurata, T.
    Nishio, K.
    Nakagawa, K.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 84 - 84
  • [5] Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein
    Zhou, Wen-jing
    Zhang, Xu
    Cheng, Chao
    Wang, Fang
    Wang, Xiao-kun
    Liang, Yong-ju
    To, Kenneth Kin Wah
    Zhou, Wang
    Huang, Hong-bing
    Fu, Li-wu
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2012, 166 (05) : 1669 - 1683
  • [6] Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein
    Zhou, Wen-jing
    Wang, Fang
    Zhang, Xu
    To, Kenneth Kin Wah
    Huang, Hong-bing
    Fu, Li-Wu
    [J]. CANCER RESEARCH, 2012, 72
  • [7] ALK GENE REARRANGEMENTS AND THE DEVELOPMENT OF PF-02341066 IN NSCLC
    Camidge, D. R.
    Christensen, J.
    Bang, Y. J.
    Shaw, A. T.
    Costa, D. B.
    Salgia, R.
    Dezube, B. J.
    Shapiro, G. I.
    Janne, P. A.
    Maki, R. G.
    Solomon, B.
    Kwak, E. L.
    Tan, W.
    Shreeve, S. M.
    Wilner, K. D.
    Clark, W. J.
    Iafrate, A. J.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 21 - 21
  • [8] CLINICAL ACTIVITY OF CRIZOTINIB (PF-02341066), IN ALK-POSITIVE PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)
    Camidge, D. R.
    Bang, Y.
    Iafrate, A. J.
    Kwak, E. L.
    Maki, R. G.
    Solomon, B.
    Ou, S. I.
    Salgia, R.
    Shaw, A.
    Clark, J.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 123 - 123
  • [9] Inhibition of ALK mutated neuroblastomas by the selective inhibitor PF-02341066
    Wood, A. C.
    Laudenslager, M.
    Haglund, E. A.
    Attiyeh, E. F.
    Pawel, B.
    Courtright, J.
    Plegaria, J.
    Christensen, J. G.
    Maris, J. M.
    Mosse, Y. P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [10] Gender Specific Drug Metabolism of PF-02341066 in Rats - Role of Sulfoconjugation
    Zhong, Wei-Zhu
    Zhan, Jenny
    Kang, Ping
    Yamazaki, Shinji
    [J]. CURRENT DRUG METABOLISM, 2010, 11 (04) : 296 - 306
12345